Novel anticancer drugs based on proteolysis targeting chimeras technology : <trans-title><xref ref-type="bibr" rid="R8">ARV-110</xref></trans-title> and <trans-title><xref ref-type="bibr" rid="R9">ARV-471</xref></trans-title><xref ref-type="bibr" rid="R8">ARV-110</xref><xref ref-type="bibr" rid="R9">ARV-471</xref>

doi:10.3969/j.issn.1672-3384.2020.01.009

PDF(1179 KB)

Clinical Medication Journal ›› 2020, Vol. 18 ›› Issue (1) : 36-39. DOI: 10.3969/j.issn.1672-3384.2020.01.009

Novel anticancer drugs based on proteolysis targeting chimeras technology : ARV-110 and ARV-471ARV-110ARV-471

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2020, 18(1): 36-39 https://doi.org/10.3969/j.issn.1672-3384.2020.01.009

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

ARV-110 and ARV-471ARV-110ARV-471" title="Share on Weibo" target="_blank">

PDF(1179 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2019-11-25	2020-01-31
Issue Date
2020-01-31

Please choose a citation manager

Content to export